Global Health Economics & Outcomes Research (HEOR) Director

Overview

As Director Global HEOR, you will lead international value evidence generation to support access for Ipsen products across development stages. You will work with cross-functional teams to build payer-ready evidence and lead HTA planning, leveraging RWE and PRO data. This role initially focuses on Rare Disease with potential expansion to other areas, shaping pricing, market access, and global value propositions. You will train affiliates and stay ahead of evolving payer landscapes to drive patient access.

Responsibilities

• Lead launch readiness and post-launch HEOR deliverables (literature reviews, burden of illness, unmet needs, outcomes, guidelines, network/meta-analyses, cost-effectiveness and budget impact models, Global Value Dossiers, payer propositions, objection handlers).
• Plan and execute EU HTA Regulation JCA activities aligned with product assignments.
• Communicate value evidence at conferences and in manuscripts/publications.
• Contribute to Integrated Evidence Generation Plans with cross-functional alignment.
• Lead RWE and PROs strategy to develop compelling payer value propositions.
• Support target product/value profile and trial endpoints to align with payer needs.
• Support pricing policy and market access development.
• Collaborate with local affiliates and global cross-functional teams to stay current on payer/HTA landscape.
• Provide training on value evidence for local adaptation and use.

Key requirements

• Postgraduate degree in health economics or related quantitative discipline
• 8+ years in HEOR within pharma, consultancy, or academia, international experience
• Experience with international HTA submissions
• Strong scientific analysis, interpretation, and writing skills
• Knowledge of international health care systems
• Expertise in HEOR for Oncology, Rare Disease or Neuroscience including evidence synthesis, CEA, budget impact, RWE, PROs
• Knowledge of trial design and relevant endpoints

• strong communication and storytelling
• cross-functional collaboration
• ability to influence stakeholders
• evidence synthesis (including indirect treatment comparisons and network meta-analysis)
• cost-effectiveness analysis
• budget impact modeling

…